共 50 条
- [4] TWO-YEAR EFFICACY FOLLOW-UP OF A PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN RECURRENT OR PERSISTENT HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER AFTER PREVIOUS BACILLUS CALMETTE-GUERIN TREATMENT [J]. JOURNAL OF UROLOGY, 2022, 207 (05): : E926 - E926
- [5] A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guerin Refractory Nonmuscle Invasive Bladder Cancer [J]. JOURNAL OF UROLOGY, 2011, 186 (02): : 448 - 451
- [7] Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure [J]. JOURNAL OF UROLOGY, 2013, 190 (05): : 1686 - 1691
- [8] Assessment of changes in the international prostate symptom score for patients enrolled in a phase I trial of intravesical bacillus Calmette-Guerin combined with intravenous pembrolizumab for recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus Calmette-Guerin treatment. [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16553 - E16553